A Phase 3 interventional study of Estradiol and Imvexxy in Dyspareunia, sponsored by Teva Pharmaceuticals USA. Completed at 48 sites in 3 countries. Open to female participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.
Among the 56 studies in Dyspareunia with a site in United States, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 in phase 3, and was the 49th registered.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
Browse Dyspareunia studies →8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40–90 · Women only · Healthy volunteers
Azure Biotech Inc. · Sites in United States
Ages 45–60 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 40 Years to 75 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,050 is above the median of 64 across 127 interventional studies indexed under Dyspareunia.
Median enrollment 60 across the 53 interventional studies, 200 across the 3 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Pharmaceuticals USA, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 2 studies filed under Dyspareunia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyspareunia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197568Azure Biotech Inc.Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | 2026-12-31 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Dyspareunia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females aged 40-75 years inclusive who are , with at least:
Patients who have underwent complete Hysterectomy, or in the case of patients with an intact uterus (including patients who underwent a partial hysterectomy) the later must have:
Exclusion Criteria:
Any clinically significant abnormalities on screening physical exam, assessments, , or laboratory tests such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.
Drug: Estradiol
IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.
Drug: Imvexxy
Placebo vaginal inserts. Insert vaginally once for 14 days.
Drug: Placebo
Response Rate (Vaginal Cytology and Vaginal pH)
% Responders where a "Responder" is defined as a patient with: At least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology; and Vaginal pH \< 5.0 with a change from baseline vaginal pH of at least 0.5
Time frame: 15 days
Change in Most Bothersome Symptom (Dyspareunia)
Mean change from baseline to Day 15 in dyspareunia score (the self-identified most bothersome symptom in women with VVA). On a scale of 0 to 3, where 0 = none, 1=mild, 2=moderate and 3 = severe
Time frame: 15 days
Treatment Success in Most Bothersome Symptom
proportion of patients in each treatment group that are considered a Treatment Success at the end of the treatment period evaluated on Day 15. A "Treatment Success" is defined as a score of 0 or 1 on Day 15 for dyspareunia (the self-identified most bothersome symptom at baseline).On a scale of 0 to 3 where 0 = none, 1=mild, 2=moderate and 3 = severe
Time frame: 15 days
| Milestone | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts |
|---|---|---|---|
| Started | 353 | 348 | 349 |
| Completed | 343 | 344 | 346 |
| Not completed | 10 | 4 | 3 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 2 |
| Withdrew: Non compliance with study drug | 0 | 1 | 0 |
| Withdrew: Prohibited medication | 1 | 0 | 0 |
| Withdrew: Randomized in error | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 |
% Responders where a "Responder" is defined as a patient with: At least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology; and Vaginal pH \< 5.0 with a change from baseline vaginal pH of at least 0.5
| Participants | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg |
|---|---|---|
| Response Rate (Vaginal Cytology and Vaginal pH) | 17 | 15 |
Mean change from baseline to Day 15 in dyspareunia score (the self-identified most bothersome symptom in women with VVA). On a scale of 0 to 3, where 0 = none, 1=mild, 2=moderate and 3 = severe
| units on a scale | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg |
|---|---|---|
| Change in Most Bothersome Symptom (Dyspareunia) | -1.43 ± 0.049 | -1.56 ± 0.049 |
proportion of patients in each treatment group that are considered a Treatment Success at the end of the treatment period evaluated on Day 15. A "Treatment Success" is defined as a score of 0 or 1 on Day 15 for dyspareunia (the self-identified most bothersome symptom at baseline).On a scale of 0 to 3 where 0 = none, 1=mild, 2=moderate and 3 = severe
| Participants | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg |
|---|---|---|
| Treatment Success in Most Bothersome Symptom | 220 | 238 |
Collected over 15 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estradiol Vaginal Inserts, 4 mcg | 54/349 (15.5%) | 1/349 (0.3%) | 54/349 (15.5%) |
| IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | 57/345 (16.5%) | 0/345 (0%) | 57/345 (16.5%) |
| Placebo Vaginal Inserts | 49/349 (14%) | 0/349 (0%) | 49/349 (14%) |
| Event | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts |
|---|---|---|---|
| PancreatitisHepatobiliary disorders | 1/349 | 0/345 | 0/349 |
| Idiopathic Intercranial HypertensionCardiac disorders | 0/349 | 0/345 | 0/349 |
| Event | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts |
|---|---|---|---|
| Administration Site PainGeneral disorders | 15/349 | 15/345 | 11/349 |
| HeadacheNervous system disorders | 9/349 | 10/345 | 6/349 |
| Administration Site PruritusGeneral disorders | 4/349 | 4/345 | 6/349 |
| Administration Site InfectionInfections and infestations | 3/349 | 5/345 | 2/349 |
| Abdominal DistensionGastrointestinal disorders | 1/349 | 3/345 | 5/349 |
| Abdominal PainGastrointestinal disorders | 3/349 | 4/345 | 4/349 |
| Administration Site DischargeGeneral disorders | 4/349 | 4/345 | 1/349 |
| Administration Sire DiscomfortGeneral disorders | 0/349 | 4/345 | 3/349 |
| NauseaGastrointestinal disorders | 2/349 | 3/345 | 0/349 |
| Abdominal DiscomfortGastrointestinal disorders | 0/349 | 2/345 | 1/349 |
Although 1050 patients were enrolled, only 1043 administered at least one dose of the investigational product.
| Age, Categorical(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 259 | 266 | 270 | 795 |
| >=65 years | 90 | 79 | 79 | 248 |
| Age, Continuous(years) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 6.7 | 59.5 ± 6.3 | 59.5 ± 6.4 | 59.7 ± 6.5 |
| Sex: Female, Male(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| Female | 349 | 345 | 349 | 1043 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| Hispanic or Latino | 234 | 236 | 228 | 698 |
| Not Hispanic or Latino | 115 | 109 | 121 | 345 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 9 | 10 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 35 | 35 | 25 | 95 |
| White | 305 | 296 | 308 | 909 |
| More than one race | 1 | 4 | 3 | 8 |
| Unknown or Not Reported | 0 | 1 | 2 | 3 |
| Postmenopausal Status(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| Natural (Spontaneous Amerorrhea) | 244 | 260 | 250 | 754 |
| Hysterectomy Without Bilateral Oophorectomy | 50 | 52 | 51 | 153 |
| Bilateral Oophorectomy With or Without Hysterectomy | 49 | 32 | 45 | 126 |
| Other | 6 | 1 | 3 | 10 |
| Vaginal Dryness(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| None | 10 | 6 | 6 | 22 |
| Mild | 44 | 41 | 46 | 131 |
| Moderate | 181 | 191 | 191 | 563 |
| Severe | 114 | 107 | 106 | 327 |
| Vaginal/Vulvur Irritation/Itching(Participants) | Estradiol Vaginal Inserts, 4 mcg | IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg | Placebo Vaginal Inserts | Total |
|---|---|---|---|---|
| None | 121 | 118 | 116 | 355 |
| Mild | 76 | 90 | 84 | 250 |
| Moderate | 109 | 94 | 105 | 308 |
| Severe | 43 | 43 | 44 | 130 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Mar 2024, 16 months.
Results were first posted in Sep 2026, 2 years 6 months after primary completion.
Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's 16 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol